Acute hyperglycemia induces podocyte apoptosis by monocyte TNF-α release, a process attenuated by vitamin D and GLP-1

Rong M Zhang1, Jisu Oh1, Burton M Wice1

  • 1Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.

Insights

Acute hyperglycemia episodes in diabetes promote inflammation, leading to kidney podocyte damage. Vitamin D may protect against this, and GLP-1 receptor activation offers a potential therapeutic strategy for diabetic kidney disease.

Area of Science:

  • Nephrology
  • Endocrinology
  • Immunology

Background:

  • Diabetic kidney disease (DKD) risk persists despite glycemic control.
  • Vitamin D deficiency and acute hyperglycemia (AH) are linked to DKD progression.
  • Residual risk suggests other contributing factors to DKD.

Purpose of the Study:

  • Investigate if AH directly harms podocytes or promotes inflammatory macrophages.
  • Determine if vitamin D deficiency exacerbates AH-induced podocyte injury.
  • Explore the role of GLP-1 receptor activation in mitigating AH effects.

Main Methods:

  • Exposed human monocytes/macrophages to AH (16.7 mM D-glucose).
  • Assessed podocyte apoptosis, TNF-α secretion, oxidative/ER stress, ADAM17/iRhom2 expression.
  • Investigated effects of vitamin D levels and GLP-1 receptor agonist.

Main Results:

  • AH did not directly induce podocyte apoptosis but increased monocyte TNF-α secretion.
  • AH-induced TNF-α was inversely correlated with serum 25(OH)D levels.
  • GLP-1 receptor activation reduced TNF-α release and podocyte apoptosis.

Conclusions:

  • AH contributes to DKD via monocyte-derived TNF-α, not direct podocyte injury.
  • Adequate vitamin D may attenuate AH-driven podocyte apoptosis.
  • GLP-1 receptor activation shows potential for preventing AH-related DKD progression.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
858
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.1K